2H-[1,2,3]三唑并[4,5-f]喹喔啉 | 233-93-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2H-[1,2,3]三唑并[4,5-f]喹喔啉
• 英文名称: 2H-1,2,3-Triazolo[4,5-f]quinoxaline
• 英文别名: 2H-triazolo[4,5-f]quinoxaline
• CAS: 233-93-2
• 化学式: C₈H₅N₅
• mdl: MFCD18814098
• 分子量: 171.16
• InChiKey: XSJMOLCRLLDSFM-UHFFFAOYSA-N

物化性质

• 沸点：
  426.4±48.0 °C(Predicted)
• 密度：
  1.571±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS
  申请人：Deleuze-Masquefa Carine

  公开号：US20100249142A1

  公开（公告）日：2010-09-30

  Imidazo[1,2-a]quinoxaline compounds for the treatment of cancers as well as pharmaceutical compositions that include these compounds and their uses in therapy. The compound of general formula (I):

  咪唑并[1,2-a]喹噁啉化合物用于治疗癌症，以及包括这些化合物的药物组合物和它们在疗法中的用途。通式(I)的化合物：
• Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer
  申请人：Universite de Montpellier

  公开号：US20180016278A1

  公开（公告）日：2018-01-18

  The invention relates to imidazo[1,2-a]quinoxaline compounds of formula (I) for the treatment of cancer, the pharmaceutical compositions comprising said chemical compounds, and the therapeutic uses thereof.

  该发明涉及公式（I）的咪唑并[1,2-a]喹喔啉化合物，用于治疗癌症，包括该化合物的药物组合物，以及其治疗用途。
• QUINOXALINE COMPOUND
  申请人：Kaizawa Hiroyuki

  公开号：US20110319385A1

  公开（公告）日：2011-12-29

  [Problem] Provided is a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like. [Means for Solution] The present inventors have investigated a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like, and thus, have found that an imidazoquinoxaline compound or a triazoloquinoxaline compound has a PDE9-inhibiting action, thereby completing the present invention. The imidazoquinoxaline compound or the triazoloquinoxaline compound of the present invention has a PDE9-inhibiting action and can be used as an agent for preventing and/or treating storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.

  提供一种具有PDE9抑制作用的化合物，可用作治疗和/或预防储存功能障碍、排尿功能障碍、膀胱/尿道疾病等药剂的活性成分。现有发明人研究了一种具有PDE9抑制作用的化合物，可用作治疗和/或预防储存功能障碍、排尿功能障碍、膀胱/尿道疾病等药剂的活性成分，因此，发现咪唑喹喔啉化合物或三唑喹喔啉化合物具有PDE9抑制作用，从而完成了本发明。本发明的咪唑喹喔啉化合物或三唑喹喔啉化合物具有PDE9抑制作用，可用作预防和/或治疗储存功能障碍、排尿功能障碍、膀胱/尿道疾病等药剂。
• [EN] PYRIMIDINES DERIVATIVES AS ADENOSINE RECEPTORS LIGANDS<br/>[FR] UTILISATION DE DERIVES DE PYRIMIDINES EN TANT QUE LIGANDS DES RECEPTEURS DE L'ADENOSINE
  申请人：UNIV LEIDEN

  公开号：WO2005033085A1

  公开（公告）日：2005-04-14

  Use of a compound of formula (I) wherein R and R' are selected from hydrogen, alkyl, alkenyl, alkynyl, or aryl; R'' and R''' are selected from hydrogen, acyl, thio-acyl, seleno-acyl, alkyl, alkenyl, alkynyl, or aryl; or a pharmaceutically acceptable salt thereof to interact with the adenosine receptors in the beneficial treatment or prevention of a (dis)order arising from the said receptors. The invention also provides pharmaceutical compositions comprising a compound according to the present invention. The invention further relates to the use of said compositions to treat and/or prevent a variety of diseases.

  使用式(I)的化合物，其中R和R'选自氢、烷基、烯基、炔基或芳基；R''和R'''选自氢、酰基、硫酰基、硒酰基、烷基、烯基、炔基或芳基；或其药学上可接受的盐与腺苷受体相互作用，有益地治疗或预防由所述受体引起的（失）调节。该发明还提供了包含根据本发明的化合物的药物组合物。该发明还涉及使用该类组合物来治疗和/或预防各种疾病。
• 2,6,8, Trisubstituted 1-deazapurines and their different uses
  申请人：Chang Lisa Chung Wai

  公开号：US20080139608A1

  公开（公告）日：2008-06-12

  The invention provides a compound having the structure of general formula (I): or a salt thereof, wherein, R represents hydrogen (except when R′=H), halogen, (substituted) alkyl except —CH 3 , (substituted) alkenyl, (substituted) alkynyl, or (substituted) —(CH 2 ) n -aryl; R′ represents hydrogen (except when R=H), halogen, (substituted) alkyl except —CH 3 , (substituted) alkenyl, (substituted) alkynyl, or (substituted) —CH 2 ) n -aryl; R″ represents hydrogen, —(CH 2 ) n -hydroxyl, halogen, acyl, thio-acyl, seleno-acyl, (substituted) alkyl, (substituted) alkenyl, (substituted) alkynyl, or (substituted) —(CH 2 ) n -aryl; and n is a number in the range from 0 to 10. The invention further provides pharmaceutical compositions comprising said compound, and the use of said compound to treat and/or prevent a variety of diseases.

  本发明提供了具有通式（I）的化合物或其盐，其中，R代表氢（除非R′=H），卤素，（取代）烷基（除CH3），（取代）烯基，（取代）炔基或（取代）-（CH2）n-芳基；R′代表氢（除非R=H），卤素，（取代）烷基（除 ），（取代）烯基，（取代）炔基或（取代）-（ ）n-芳基；R″代表氢，-（ ）n-羟基，卤素，酰基，硫酰基，硒酰基，（取代）烷基，（取代）烯基，（取代）炔基或（取代）-（ ）n-芳基；n为0到10之间的数字。本发明还提供了包含上述化合物的药物组合物，以及使用该化合物治疗和/或预防各种疾病的方法。